Jennison Associates LLC Buys 18,219 Shares of Encompass Health Corporation $EHC

Jennison Associates LLC grew its stake in Encompass Health Corporation (NYSE:EHC) by 3.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 578,998 shares of the company’s stock after buying an additional 18,219 shares during the quarter. Jennison Associates LLC’s holdings in Encompass Health were worth $56,006,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. WPG Advisers LLC lifted its position in shares of Encompass Health by 73.3% during the 4th quarter. WPG Advisers LLC now owns 324 shares of the company’s stock valued at $34,000 after buying an additional 137 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Encompass Health in the 4th quarter worth approximately $37,000. Assetmark Inc. raised its stake in Encompass Health by 89.6% during the 1st quarter. Assetmark Inc. now owns 455 shares of the company’s stock worth $44,000 after acquiring an additional 215 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Encompass Health by 36,200.0% during the third quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after purchasing an additional 362 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new position in Encompass Health during the fourth quarter valued at approximately $55,000. Institutional investors own 97.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EHC. Weiss Ratings cut shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. TD Cowen started coverage on shares of Encompass Health in a research note on Thursday, May 28th. They set a “buy” rating and a $125.00 target price on the stock. Barclays dropped their target price on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Leerink Partners set a $152.00 price objective on Encompass Health in a research report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Encompass Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.86.

Encompass Health Price Performance

EHC stock opened at $112.24 on Monday. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99. The company’s fifty day moving average price is $104.47 and its 200-day moving average price is $103.59. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The company has a market capitalization of $11.13 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 2.45 and a beta of 0.74.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.51 by $0.09. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. Encompass Health’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period last year, the company posted $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, equities analysts anticipate that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st were given a dividend of $0.19 per share. The ex-dividend date was Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is presently 12.69%.

Insider Activity

In other news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the sale, the executive vice president directly owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.80% of the company’s stock.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.